Background-Hypokalemia is known to promote ventricular arrhythmias, especially in combination with class III antiarrhythmic drugs like dofetilide. Here, we evaluated the underlying molecular mechanisms. Methods and Results-Arrhythmias were recorded in isolated rabbit and rat hearts or patch-clamped ventricular myocytes exposed to hypokalemia (1.0-3.5 mmol/L) in the absence or presence of dofetilide (1 μmol/L). Spontaneous early afterdepolarizations (EADs) and ventricular tachycardia/fibrillation occurred in 50% of hearts at 2.7 mmol/L [K] in the absence of dofetilide and 3.3 mmol/L [K] in its presence. Pretreatment with the Ca-calmodulin kinase II (CaMKII) inhibitor KN-93, but not its inactive analogue KN-92, abolished EADs and hypokalemia-induced ventricular tachycardia/ fibrillation, as did the selective late Na current (I Na ) blocker GS-967. In intact hearts, moderate hypokalemia (2.7 mmol/L) significantly increased tissue CaMKII activity. Computer modeling revealed that EAD generation by hypokalemia (with or without dofetilide) required Na-K pump inhibition to induce intracellular Na and Ca overload with consequent CaMKII activation enhancing late I Na and the L-type Ca current. K current suppression by hypokalemia and dofetilide alone in the absence of CaMKII activation were ineffective at causing EADs. Conclusions-We conclude that Na-K pump inhibition by even moderate hypokalemia plays a critical role in promoting EAD-mediated arrhythmias by inducing a positive feedback cycle activating CaMKII and enhancing late I Na . Class III antiarrhythmic drugs like dofetilide sensitize the heart to this positive feedback loop.
H ypokalemia is a commonly encountered complication of diuretic therapy in clinical settings 1 and is known to promote ventricular arrhythmias, [2] [3] [4] and to potentiate the proarrhythmic effects of class III (K channel blocking) antiarrhythmic drugs. Hypokalemia directly reduces repolarization reserve by decreasing K conductances, including the inward rectifier K current I K1 , the rapid component of the delayed rectifier K current I Kr and the transient outward current I to1 , all of which exhibit a strong allosteric dependence on extracellular K concentration [K] o . 5, 6 Therefore, it is not surprising that these effects act synergistically with K channel blocking drugs to promote early afterdepolarization (EAD)-mediated arrhythmias including torsades de pointes, polymorphic ventricular tachycardia (VT), and ventricular fibrillation (VF).
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However, suppression of K currents alone may not be sufficient to induce EAD-mediated arrhythmias. Anderson and colleagues 7, 8 previously implicated Ca-calmodulin kinase II (CaMKII) activation by the K channel blocker clofilium as playing a key factor in EAD formation by showing that clofilium activated CaMKII activity in isolated rabbit hearts. Moreover, CaMKII inhibitors abolished clofilium-induced EADs. Recently, Yang et al 9 reported that various class III antiarrhythmic drugs such as dofetilide contribute to EAD formation by activating the late Na current (I Na ) via phosphoinositide 3-kinase inhibition.
A sometimes overlooked effect of hypokalemia is Na-K pump inhibition, which may contribute to intracellular Na and Ca loading at even moderately reduced serum [K] levels (2.7 mmol/L). 10 Na-K pump inhibition also reduces repolarization reserve by suppressing outward pump current. 11 We hypothesized that Na-K pump inhibition by clinically relevant moderate hypokalemia may play an important role in activating CaMKII to promote EADs and ventricular arrhythmias even in the absence of a class III antiarrhythmic drug. Indeed, EADs induced by moderate hypokalemia in isolated mouse hearts were suppressed by both nifedipine and CaMKII inhibition. 12 To test this hypothesis, we exposed rabbit and rat hearts and isolated myocytes to hypokalemia in the absence and presence of the class III antiarrhythmic drug dofetilide. We show that moderate hypokalemia, either alone or in the presence of dofetilide, causes sufficient Na-K pump inhibition and intracellular Ca accumulation to activate CaMKII, which then plays an obligatory role in causing EADs and EADmediated VT/VF by enhancing late I Na . These findings may provide insight into why the failing heart, with chronically increased levels of activated CaMKII, 13 is presensitized to the proarrhythmic effects of class III antiarrhythmic drugs even when serum [K] is normal. In addition, our findings suggest that targeting late I Na to break the CaMKII-facilitated positive feedback cycle promoting EAD formation may be a promising antiarrhythmic strategy.
Methods
The research protocol (ARC protocol #2003-063-31) was approved by the UCLA Institutional Animal Care and Use Committee following American Heart Association guidelines.
Intact Heart Optical Mapping Experiments
Hearts removed from anesthetized New Zealand White rabbits (4-6 months old) and male Fisher344 rats (3-4 months old) were mounted in Langendorff fashion, perfused at 37°C with Tyrode solution containing (in mmol/L): NaCl 125, NaHCO 3 24, KCl 5.4, NaH 2 PO 4 1.8, MgCl 2 0.5, CaCl 2 1.8, glucose 5.5, albumin 100 mg/L, pH 7.4 gassed with 95%O 2 -5%CO 2 . The added KCl was reduced for hypokalemia. Hearts were stained with RH237 for voltage mapping with the use of cytochalasin D (5 μmol/L) to eliminate motion artifact. 14, 15 Extracellular electrograms were recorded continuously by using bipolar Ag-AgCl electrodes, and, in some experiments, intracellular membrane potential was recorded from epicardial myocytes by using glass microelectrodes.
Isolated Ventricular Myocyte Patch-Clamp Studies
Myocytes were enzymatically isolated from 3-to 4-month-old New Zealand white male rabbits and used within 8 hours for whole-cell patch -clamp studies as described previously. 16 The pipette solution contained (in mmol/L) K-aspartate 110, KCl 30, NaCl 5, HEPES 10, EGTA 0.0 to 0.1, MgATP 5, creatine phosphate 5, and cAMP 0.1 (pH 7.2 adjusted with KOH). Cells were superfused at 37°C with standard Tyrode solution containing (in mmol/L) NaCl 136, KCl 5.4 (reduced in hypokalemia experiments), NaH 2 PO 4 0.33, CaCl 2 1.8, MgCl 2 1, HEPES 10, and glucose 10 (pH 7.4 adjusted with NaOH) unless otherwise indicated. To inhibit CaMKII, KN-93 (or KN-92 as control) was added to the superfusate, or CaMKII inhibitor peptide autocamptide-2-related inhibitor peptide (AIP; 2 μmol/L) was added to the patch electrode solution and allowed to equilibrate for 20 to 30 minutes after patch rupture before experimental intervention. To selectively block late I Na , GS-967 (l μmol/L) was added to the super-perfusate. 
Computer Modeling
Simulations were performed using a rabbit ventricular myocyte action potential (AP) model, 18 
Statistical Analyses
The conventional percentile bootstrap-resampling approach with 10 000 replications was used for estimating confidence intervals (CIs). 19 Nonparametric statistical tests (Wilcoxon rank sum test for CaMKII activity differences, Wilcoxon signed rank test for action potential duration [APD] differences, and Fisher exact test for differences in VT/VF in unpaired hearts in the absence and presence of dofetilide) were used to assess P values. Kaplan-Meier curves were constructed to compare the time to onset of VT/VF at different [K], using the pairwise log rank test with Bonferroni correction for multiple comparisons to estimate P values.
Results

Moderate Hypokalemia Induces EAD-Mediated VT/VF in Isolated Rabbit and Rat Hearts
Exposure of isolated rabbit hearts to moderate hypokalemia (2.7 mmol/L) prolonged APD at 90% repolarization (APD 90 ) from 207 ms (95% CI, 204-210 ms) to 260 ms (95% CI, 258-268 ms; n=10, P=0.005), associated with a 13% (95% CI, 10%-17%) increase in AP amplitude (n=5) consistent with hyperpolarization of the resting membrane potential. No significant arrhythmias were observed initially, but after delays of 28, 33, and 80 minutes, 3 of 10 hearts developed episodes of VT/VF arising spontaneously from sinus rhythm. Simultaneous intracellular microelectrode and pseudo-ECG recordings showed that the VF was initiated by EAD-mediated triggered activity causing focal VT with cycle length (CL) 112 ms (95% CI, 105-123 ms) that spontaneously emerged from sinus rhythm (mean CL, 486 ms [95% CI, 445-528 ms]), as illustrated in Figure 1A . Focal VT degenerated to VF (mean CL, 66 ms [95% CI, 61-70 ms]) within 1 to 2 s after its onset, consistent with EAD-mediated mixed focal-reentrant VF described previously. 20 To determine if VT/VF during moderate hypokalemia was unique to rabbits as a species, we also exposed isolated rat hearts to the same level of moderate hypokalemia (2.7 mmol/L Figure 1B . Triggered activity causing focal VT degenerated to VF within 1 to 2 s, with a mean CL during VF of 48 ms (95% CI, 37-59 ms) during VF. Delayed afterdepolarizations were also occasionally observed and triggered single beats, but no sustained arrhythmias ( Figure 1B, arrows) . During optical mapping, the October 20, 2015 onset of EAD-mediated triggered activity was captured in 5 rat hearts. In the example shown in Figure 2 , 2 consecutive runs of EAD-mediated triggered activity arose from the LV base of an isolated rat heart, causing focal VT at mean CL of 85 ms (95% CI, 71-99 ms). Four isolated rat hearts exposed to hypokalemia for 90 minutes with 10 μmol/L nifedipine present remained in sinus rhythm throughout, but developed VT/ VF after nifedipine was removed ( Figure I 
Dofetilide Sensitizes Isolated Rabbit Hearts to Hypokalemia-Induced VT/VF
We next tested the level of hypokalemia required to induce VT/VF in isolated rabbit hearts. 
CaMKII Inhibitor KN-93 and the Late I Na Blocker GS-967 Prevent Hypokalemia-Induced VT/VF
Because hypokalemia and dofetilide affect K currents immediately, the delay between the onset of hypokalemia and EADmediated VT/VF (from 9.6 to 55 minutes depending on the degree of hypokalemia) implies that additional factors are at play. Based on previous reports that CaMKII inhibition suppressed EADs induced by clofilium in rabbits, 7, 8 we investigated whether CaMKII inhibition prevented arrhythmias induced by hypokalemia alone. We Because an important CaMKII target implicated in EAD formation is late I Na , 21 we exposed 4 isolated rabbit hearts to severe hypokalemia (2.0 mmol/L) in the presence of the selective late I Na blocker GS-967 (1 μmol/L). 17 In all 4 hearts studied, pretreatment with GS-967 prevented VT/VF during a 30-minute exposure to 2.0 mmol/L [K] o ( Figure 4D and 4E).
To determine directly whether moderate hypokalemia increased basal (autophosphorylated) CaMKII activity, we measured tissue CaMKII activity levels in isolated rabbit ventricles. During baseline arterial perfusion with 5.4 mmol/L [K] o , basal tissue CaMKII activity in 3 hearts averaged 47% (95% CI, 44-49) of maximal CaMKII activity determined by adding saturating Ca and CaM to the same tissue sample. Thirty minutes after lowering [K] o to 2.7 mmol/L in a separate group of 5 hearts, CaMKII activity increased to 71% (95% CI, 50-92) of maximal (P=0.025; Figure 5 ). Although 3 of these 5 hearts developed transient (1-2 minutes in 2 hearts) or persistent VT/VF (1 heart) during the hypokalemic period, the elevation in CaMKII activity was similar to 2 hearts that remained in sinus rhythm throughout (open circles, Figure 5 ).
CaMKII Inhibitors and the Late I Na Blocker GS-967 Suppress Hypokalemia-Induced EADs in Isolated Ventricular Myocytes
Moderate hypokalemia (2.7 mmol/L) readily induces bradycardia-dependent EADs in isolated rabbit and rat ventricular myocytes. 16, 22, 23 Figure 6A shows that in isolated rabbit myocytes, hypokalemia-induced EADs (second row) were unaffected by KN-92 (third row), but completely suppressed by KN-93 at the equivalent concentration of 1 μmol/L (fourth row). EADs recurred when KN-93 was washed out (not shown). Similar results were obtained in 4 other myocytes.
The more selective CaMKII inhibitor peptide AIP also suppressed EADs induced by 2. Together with the intact heart experiments, these findings indicate that CaMKII activation is required for hypokalemia to induce EAD-mediated VT/VF, with CaMKII-induced potentiation of late I Na a required component.
Computer Simulations Reveal CaMKII Activation as a Key Positive Feedback Element in Hypokalemia-Induced EADs
Hypokalemia can increase intracellular Ca loading both by prolonging APD and by inhibiting the Na-K pump. 10 To dissect the relative importance of these factors in activating CaMKII during moderate hypokalemia (2.7 mmol/L), we performed computer simulations using a rabbit ventricular AP and Ca-cycling model 18 incorporating CaMKII signaling. 24 The reported effects of CaMKII activation on I Ca,L and late I Na , 21, 25, 26 both of which are known to potentiate EADs, 27 were simulated (see Methods). To analyze which factors (APD prolongation, Na-K pump inhibition, CaMKII activation) were essential for EADs to develop, we performed additional simulations (Table) . If intracellular [Na] was clamped to its control value of 10.9 mmol/L to prevent any increase during hypokalemia, APD prolonged modestly, but Ca accumulation and CaMKII activation was attenuated, such that no EADs developed (column d), even when APD was further prolonged by blocking I Kr to simulate the effects of a class III antiarrhythmic drug like dofetilide (column e). These findings indicate that APD prolongation alone, owing to the inhibition of K currents by hypokalemia and a class III antiarrhythmic drug, does not elevate intracellular Ca sufficiently to cause EADs in this model unless hypokalemiainduced Na-K pump inhibition is also present. Conversely, if the suppressant effects of hypokalemia on I Kr and I K1 were selectively eliminated by making both conductances insensitive to [K] o , while preserving hypokalemia-induced Na-K pump inhibition, intracellular Na and Ca accumulation still increased sufficiently to activate CaMKII and caused EADs to appear after only a slight delay from 10.9 to 11.1 minutes (column f). If I Kr was blocked to simulate a class III antiarrhythmic agent under the same conditions, the time to EAD onset modestly accelerated to 9.8 minutes (column g). These findings indicate that, in this model, hypokalemia-induced Na-K pump inhibition resulting in CaMKII activation is sufficient to cause EADs, whether or not K conductances are concomitantly reduced.
Discussion
In this study, we have documented in 2 species with different underlying AP characteristics that moderate hypokalemia, at levels commonly observed clinically, is a potent inducer of EAD-mediated arrhythmias, even in the absence of QT-prolonging drugs. The most novel contribution is our demonstration that the mechanism depends not only on K current suppression by hypokalemia, but also on hypokalemia-induced Na-K pump inhibition leading to Na and Ca overload and CaMKII activation. CaMKII activation initiates a positive feedback cascade, further exacerbating Na and Ca accumulation by inducing late I Na and increasing I Ca,L , which progressively impair repolarization reserve (Figure 8 ). Thus, our findings provide insight into why most experimental models in which EAD-mediated arrhythmias were induced by K channel blocking drugs in normal heart tissue also included hypokalemia (and often hypomagnesemia) as a cofactor. This is reasonable, given clinical observations that hypokalemia often accompanies torsades de pointes induced by class III antiarrhythmic drugs, 28, 29 but also emphasizes the critical independent role that hypokalemia plays via Na-K pump inhibition with consequent CaMKII activation. In our isolated rabbit heart preparation, dofetilide, despite significantly prolonging APD, was ineffective at inducing EAD-mediated arrhythmias when extracellular [K] was normal. Rather dofetilide sensitized the heart to hypokalemia, such that VT/ VF occurred at a higher extracellular [K] when dofetilide was present ( Figure 3) .
We do not mean to imply that QT prolonging drugs such as dofetilide pose no arrhythmic risk in the absence of hypokalemia. In settings in which CaMKII activity is already elevated by other factors, such as heart disease, exercise or other drugs, additional CaMKII activation via hypokalemia-induced Na-K pump inhibition may not be required to induce the positive feedback cascade in Figure 8 . In this context, the positive feedback loop between CaMKII activation and Na and Ca loading has been recently emphasized as a key factor driving maladaptive excitation-contraction coupling remodeling and arrhythmogenesis in heart failure. 13, 21 Our findings predict that this paradigm is significantly potentiated by chronic hypokalemia, a common complication of diuretic therapy in heart failure. Combined with other factors reducing repolarization reserve in heart disease, this may explain the greater proarrhythmic risk of class III antiarrhythmic drugs in diseased hearts, and also why it is easier to identify studies of druginduced torsades de pointes during normokalemia in diseased heart models, 30 in which CaMKII activity is already elevated. The traditional explanation for the proarrhythmic synergy between K channel blocking drugs and hypokalemia is that hypokalemia further reduces repolarization reserve by suppressing I Kr , I K1 , and I to , whose conductances are allosterically regulated by extracellular [K]. 5, 6 In addition, the sensitivity of some K channels to block by class III antiarrhythmic drugs is increased by hypokalemia. 31 Recently, however, Aronsen et al 10 documented significant Na-K pump inhibition by moderate hypokalemia (2.7 mmol/L) in isolated rat ventricular myocytes, sufficient to increase intracellular Na and Ca to a level inducing spontaneous diastolic Ca waves. They did not directly record triggered arrhythmias, nor did they investigate the role of CaMKII activation in their study. Nevertheless, their direct measurements of hypokalemia-induced intracellular Na and Ca accumulation are compatible with our experimental data that the same level of moderate hypokalemia increased tissue CaMKII activity ( Figure 5 ).
As analyzed quantitatively in the computer model, 2 factors contribute to hypokalemia-induced Na-K pump inhibition. Given a K 0.5 of the Na-K pump for [K] o of 1.9 mmol/L, 32 reducing [K] o from 5.4 to 2.7 mmol/L is predicted to reduce pump activity by only 21% (ie, if the membrane potential is clamped to prevent hyperpolarization and other ion concentrations are held constant). However, the Na-K pump is also electrogenic and is inhibited by membrane hyperpolarization. Thus, when hypokalemia shifts the K equilibrium potential to more negative values, the resting membrane potential also becomes hyperpolarized (from -82 to -100 mV in isolated rabbit ventricular myocytes), which is predicted to reduce pump activity by 28% if all ion concentrations are held constant. The combined effects of both reduced extracellular [K] and hyperpolarization acutely reduced Na-K pump activity by 43% in the model, before any other ion concentrations besides [K] o changed. These findings agree quantitatively with the direct measurements of Na-K pump current in isolated rat myocytes by Aronsen et al, 10 which decreased by ≈50% at 2.7 mmol/L [K]. 33 Together, these factors contribute to a slow rise in intracellular [Na] , which inhibits the ability of the Na-Ca exchanger to remove Ca from the cell (Figure 8) .
However, Na-K pump inhibition and APD prolongation by themselves were not sufficient to induce either dramatic increases in intracellular Ca or EADs, unless the effects of CaMKII activation on the I Ca,L and late I Na current were also simulated. When these effects of CaMKII are added, positive feedback loops are introduced (Figure 8 ) -as CaMKII is activated, the resulting phosphorylation of L-type Ca channels augments their peak current, 25 which further increases Ca loading during the action potential. CaMKII-dependent phosphorylation of Na channels also increases late I Na , exacerbating Na loading. 21, 26 As shown in Figure 7 , these effects accelerate intracellular Na and Ca accumulation during hypokalemia, in addition to further compromising repolarization reserve owing to hypokalemia-induced K conductance suppression. Thus, in the model, the reduction of repolarization reserve by hypokalemia was not, by itself, sufficient to induce EADs, even if I Kr was also blocked to simulate a class III antiarrhythmic drug such as dofetilide (Table) . Na-K pump inhibition leading to CaMKII activation with I Ca,L and I Na modification was required for EADs to develop.
Limitations
In the intact heart experiments, we could not directly measure increases in intracellular Ca expected to activate CaMKII, although we documented increased tissue CaMKII activity during moderate hypokalemia (2.7 mmol/L). Microelectrode and optical mapping recordings were confined to the epicardium, and we cannot exclude the possibility that arrhythmias resulting from EADs, delayed afterdepolarizations, or other mechanisms arose from deeper levels. Nevertheless, we did directly record EADs and triggered activity from epicardial myocytes (eg, Figures 1 and 2) . In previous studies, 14, 34 we also showed that endocardial cryoablation did not prevent EADs and EAD-mediated arrhythmias induced by a variety of stressors.
It has been reported that hypokalemia induces removal of K r channels from the surface membrane. 35 However, the time course (hours) is too slow to explain the ≈10 to 55 minutes delay before the onset of VT/VF in our isolated rabbit and rat heart models. Moreover, I Kr is not a major repolarizing current in the rat ventricle, so that its removal from the surface membrane should be of minor consequence. 36 Similarly, our experiments with dofetilide were too short term to account for late I Na activation augmentation attributable to phosphoinositide 3-kinase inhibition, because this effect required >30 minutes and probably several hours. 9 Regarding the computer modeling, we simulated only the reported effects of CaMKII on late I Na and I Ca,L amplitude relevant to EAD formation. However, CaMKII also affects I Ca,L kinetics, and additional targets, as well, involved in excitationcontraction coupling, Ca cycling and repolarization, such as ryanodine receptors, I K1 and I to , that may also play important roles in EAD formation, and promoting Ca cycling abnormalities predisposing to Ca waves and delayed afterdepolarizations, as well. 13 We did observe delayed afterdepolarizations accompanying EADs in some hearts ( Figure 1B ), although they did not appear to play an important role in initiating VT/ VF. The CaMKII-mediated effects on I Ca,L and late I Na were sufficient to explain the experimental observations on EADs without incorporating these additional aspects, and block of late I Na alone using GS-967 was sufficient to prevent EADs and EAD-mediated arrhythmias in both isolated myocytes and intact hearts. We assumed a single K 0.5 value (1.9 mmol/L) for the [K] o dependence of the Na-K pump corresponding to the dominant α1 isoform in heart. 32, 37 However, the α2 isoform comprises ≈12% to 25% in rodents, 37, 38 and has a higher K 0.5 (2.9 mmol/L), 32 which, overall, would exacerbate Na-K pump inhibition by hypokalemia. The K 0.5 of both isoforms are also modulated dynamically by protein kinase C/protein kinase A-mediated phosphorylation of phospholemman, 32 which we did not simulate.
Clinical Implications
Hypokalemia, defined as a serum level <3.5 mmol/L, is a common electrolyte abnormality in clinical practice. Serum K values <3.6 mmol/L were seen in >20% of hospitalized patients 39 and in as many as 10% to 40% of patients on thiazide diuretics. 1 Hypokalemia is known to promote ventricular arrhythmias and sudden cardiac death, [2] [3] [4] was present in 49% of patients resuscitated from out-of-hospital VF, 40 has been implicated in electrical storm, 41 and is also commonly associated with drug-induced torsades de pointes. 42 Our findings in rabbit and rat hearts provide insight into the molecular basis for these proarrhythmic effects of hypokalemia, demonstrating that clinically relevant levels (2.0-3.5 mmol/L) have the potential to produce life-threatening arrhythmias even in the absence of K channel blocking drugs or frank heart disease. In settings in which repolarization reserve is already compromised, such as heart failure and congenital or acquired long QT syndromes, moderate hypokalemia is likely to be even more arrhythmogenic and should be rigorously avoided during diuretic therapy. Patients with heart failure, in whom CaMKII activity is already elevated and the repolarization reserve is reduced because of electric remodeling, may be especially vulnerable. In addition, because CaMKII is already activated in heart failure, class III antiarrhythmic drugs may be arrhythmogenic even when [K] o is normal. Finally, our findings with GS-967 suggest that the proarrhythmic effects of hypokalemia and class III antiarrhythmic drugs can be abrogated by blocking late I Na , a key target of CaMKII which, by increasing intracellular Na and Ca loading, fuels the positive feedback loop that further accelerates CaMKII activation (Figure 8 ), enhancing the onset of EAD-mediated arrhythmias inhibition.
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Supplemental Material Supplemental Methods
The research protocol (ARC protocol #2003-063-31) was approved by the UCLA Institutional Animal Care and Use Committee following the guidelines of American Heart Association.
Intact heart optical mapping experiments
New Zealand White rabbits (4-6 month old) and male Fisher344 rat (3-4 month old) were used in this study. The hearts of the anesthetized rabbits or rats were removed and the ascending aorta was cannulated for retrograde perfusion through the coronary ostia in the Langendorff fashion as we previously described.
1, 2 The hearts (N=5) were then stained with RH237 for voltage fluorescent optical imaging as described previously. 3 Cytochalasin D (5 μmol/l) was added to the perfusate to eliminate motion artifact during optical recordings. 1, 2 The stained heart was excited with green light (LED) at 532 nm and the emitted fluorescence was collected using CMOS camera (MiCAM Ultima, BrainVision, Tokyo, Japan) at 1 ms/frame and 100x100 pixels 
Isolated ventricular myocyte patch clamp studies
Young adult (3-to 4-month-old) New Zealand white male rabbits (1.7-2.0 kg) were injected intravenously once with heparin sulfate (1,000 U) and sodium pentobarbital (100 mg/kg). Following confirmation of adequate anesthesia (absence of pedal withdrawal reflex, corneal reflex, and motor response to pain stimuli by scalpel tip), hearts were rapidly excised and perfused for myocyte isolation.
Freshly isolated single ventricular myocytes were used within 8 hours for whole-cell patch clamp studies as described previously 4 
Dofetilide sensitization of a rabbit heart to hypokalemia-induced VT/VF.
A rabbit heart which failed to develop VT/VF after 90 mins of moderate hypokalemia (2.7 mmol/l) subsequently developed VT/VF after dofetilide was added (Fig. S3) . Figure S3 . Dofetilide sensitization of a rabbit heart to hypokalemia-induced VT/VF. A heart in sinus rhythm (A) which failed to develop VT/VF after 90 mins of exposure to 2.7 mmol/l (B), which subsequently developed VT/VF within 2 min after dofetilide was added (C). 
Role of CaMKII activation in hypokalemia-induced VF in isolated rat hearts
